This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Henderson, B. W. Articles by Dougherty, T. J. Search for Related Content PubMed PubMed Citation Articles by Henderson, B. W. Articles by Dougherty, T. J.

An in Vivo Quantitative Structure-Activity Relationship for a Congeneric Series of Pyropheophorbide Derivatives as Photosensitizers for Photodynamic Therapy¹

Departments of Radiation Biology [B. W. H., D. A. B., R. K. P., L. A. V., K. R. W., T. J. D.], Biomathematics [W. R. G.], and Experimental Therapeutics [A. S., W. R. G.], Roswell Park Cancer Institute (RPCI), Buffalo, New York 14263

An in vivo quantitative structure-activity relationship (QSAR) study was carried out on a congeneric series of pyropheophorbide photosensitizers to identify structural features critical for their antitumor activity in photodynamic therapy (PDT). The structural elements evaluated in this study include the length and shape (alkyl, alkenyl, cyclic, and secondary analogs) of the ether side chain. C3H mice, harboring the radiation-induced fibrosarcoma tumor model, were used to study three biological response endpoints: tumor growth delay, tumor cell lethality, and vascular perfusion. All three endpoints revealed highly similar QSAR patterns that constituted a function of the alkyl ether chain length and drug lipophilicity, which is defined as the log of the octanol:water partition coefficient (log P). When the illumination of tumor, tumor cells, or cutaneous vasculature occurred 24 h after sensitizer administration, activities were minimal with analogs of log P 5, increased dramatically between log P of 5–6, and peaked between log P of 5.6–6.6. Activities declined gradually with higher log P. The lack of activity of the least-lipophilic analogs was explained in large part by their poor biodistribution characteristics, which yielded negligible tumor and plasma drug levels at the time of treatment with light. The progressively lower potencies of the most lipophilic analogs cannot be explained through the overall tumor and plasma pharmacokinetics of photosensitizer because tumor and plasma concentrations progressively increased with lipophilicity. When compensated for differences in tumor photosensitizer concentration, the 1-hexyl derivative (optimal lipophilicity) was 5-fold more potent than the 1-dodecyl derivative (more lipophilic) and 3-fold more potent than the 1-pentyl analog (less lipophilic), indicating that, in addition to the overall tumor pharmacokinetics, pharmacodynamic factors may influence PDT activity. Drug lipophilicity was highly predictive for photodynamic activity. QSAR modeling revealed that direct antitumor effects and vascular PDT effects may be governed by common mechanisms, and that the mere association of high levels of photosensitizer in the tumor tissue is not sufficient for optimal PDT efficiency.

¹ Supported by National Cancer Institute Grants CA55791 and CA16056.

² To whom requests for reprints should be addressed, at the Department of Radiation Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 2/14/97. Accepted 7/14/97.

This article has been cited by other articles:

				M. Seshadri, D. A. Bellnier, L. A. Vaughan, J. A. Spernyak, R. Mazurchuk, T. H. Foster, and B. W. Henderson Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy Clin. Cancer Res., May 1, 2008; 14(9): 2796 - 2805. [Abstract] [Full Text] [PDF]

				B. W. Henderson, S. O. Gollnick, J. W. Snyder, T. M. Busch, P. C. Kousis, R. T. Cheney, and J. Morgan Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of Tumors Cancer Res., March 15, 2004; 64(6): 2120 - 2126. [Abstract] [Full Text] [PDF]

				J. W. Snyder, W. R. Greco, D. A. Bellnier, L. Vaughan, and B. W. Henderson Photodynamic Therapy: A Means to Enhanced Drug Delivery to Tumors Cancer Res., December 1, 2003; 63(23): 8126 - 8131. [Abstract] [Full Text] [PDF]

				D. A. Bellnier, W. R. Greco, G. M. Loewen, H. Nava, A. R. Oseroff, R. K. Pandey, T. Tsuchida, and T. J. Dougherty Population Pharmacokinetics of the Photodynamic Therapy Agent 2-[1-Hexyloxyethyl]-2-devinyl Pyropheophorbide-a in Cancer Patients Cancer Res., April 15, 2003; 63(8): 1806 - 1813. [Abstract] [Full Text] [PDF]

				J.-Y. Matroule, G. Bonizzi, P. Morliere, N. Paillous, R. Santus, V. Bours, and J. Piette Pyropheophorbide-a Methyl Ester-mediated Photosensitization Activates Transcription Factor NF-kappa B through the Interleukin-1 Receptor-dependent Signaling Pathway J. Biol. Chem., January 29, 1999; 274(5): 2988 - 3000. [Abstract] [Full Text] [PDF]